Yesterday, Rainbow Coral Corp. announces its search for a capable investment banking firm to assist in procuring capital for the acquisition of Nano3D Biosciences (n3D) and other target companies. Rainbow BioSciences will develop new medical and research technology innovations to compete alongside companies such as Celgene Corp. (NASDAQ:CELG), Cardinal Health, Inc. (NYSE:CAH), Abbott Laboratories (NYSE:ABT) and Affymax, Inc. (NASDAQ:AFFY).
RBCC is in the process of short-listing an investment banking firm in Houston, home of the company's biosciences division. RBCC aims to work with Houston firms due to the impressive performance of the area's biotech sector. In fact, this month the Brookings Institution named the Houston regional economy the fastest-growing in North America. The firm will assist with potential capital-raise programs.
Nano3D is a fully commercialized company that has developed a breakthrough three-dimensional cell culturing system. The assistance of an investment banking firm in raising capital would allow RBCC to move forward with its acquisition plans and global marketing initiative for n3D.
For more information on Rainbow BioSciences, Rainbow Coral's biotech division, please visit rainbowbiosciences.com/investors
Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net